Genome-wide association neural networks identify genes linked to family history of Alzheimer's disease.

Journal: Briefings in bioinformatics
PMID:

Abstract

Augmenting traditional genome-wide association studies (GWAS) with advanced machine learning algorithms can allow the detection of novel signals in available cohorts. We introduce "genome-wide association neural networks (GWANN)" a novel approach that uses neural networks (NNs) to perform a gene-level association study with family history of Alzheimer's disease (AD). In UK Biobank, we defined cases (n = 42 110) as those with AD or family history of AD and sampled an equal number of controls. The data was split into an 80:20 ratio of training and testing samples, and GWANN was trained on the former followed by identifying associated genes using its performance on the latter. Our method identified 18 genes to be associated with family history of AD. APOE, BIN1, SORL1, ADAM10, APH1B, and SPI1 have been identified by previous AD GWAS. Among the 12 new genes, PCDH9, NRG3, ROR1, LINGO2, SMYD3, and LRRC7 have been associated with neurofibrillary tangles or phosphorylated tau in previous studies. Furthermore, there is evidence for differential transcriptomic or proteomic expression between AD and healthy brains for 10 of the 12 new genes. A series of post hoc analyses resulted in a significantly enriched protein-protein interaction network (P-value < 1 × 10-16), and enrichment of relevant disease and biological pathways such as focal adhesion (P-value = 1 × 10-4), extracellular matrix organization (P-value = 1 × 10-4), Hippo signaling (P-value = 7 × 10-4), Alzheimer's disease (P-value = 3 × 10-4), and impaired cognition (P-value = 4 × 10-3). Applying NNs for GWAS illustrates their potential to complement existing algorithms and methods and enable the discovery of new associations without the need to expand existing cohorts.

Authors

  • Upamanyu Ghose
    Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
  • William Sproviero
    Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
  • Laura Winchester
    Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
  • Najaf Amin
    Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
  • Taiyu Zhu
  • Danielle Newby
    Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
  • Brittany S Ulm
    King Abdulaziz University and the University of Oxford Centre for Artificial Intelligence in Precision Medicine (KO-CAIPM), Jeddah, Saudi Arabia.
  • Angeliki Papathanasiou
    Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
  • Liu Shi
    Department of Psychiatry, University of Oxford, Oxford, UK.
  • Qiang Liu
    Blood Transfusion Laboratory, Jiangxi Provincial Blood Center Nanchang 330052, Jiangxi, China.
  • Marco Fernandes
    Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
  • Cassandra Adams
    King Abdulaziz University and the University of Oxford Centre for Artificial Intelligence in Precision Medicine (KO-CAIPM), Jeddah, Saudi Arabia.
  • Ashwag Albukhari
    King Abdulaziz University and the University of Oxford Centre for Artificial Intelligence in Precision Medicine (KO-CAIPM), Jeddah, Saudi Arabia.
  • Majid Almansouri
    King Abdulaziz University and the University of Oxford Centre for Artificial Intelligence in Precision Medicine (KO-CAIPM), Jeddah, Saudi Arabia.
  • Hani Choudhry
    Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Cornelia van Duijn
    King Abdulaziz University and the University of Oxford Centre for Artificial Intelligence in Precision Medicine (KO-CAIPM), Jeddah, Saudi Arabia.
  • Alejo Nevado-Holgado
    University of Oxford, United Kingdom of Great Britain and Northern Ireland. Electronic address: alejo.nevado-holgado@psych.ox.ac.uk.